AntiPD1

PreclinicalSmall molecule

AAzienda Ospedaliera di Perugia

AntiPD1 is one of 34 small molecule programs targeting Cutaneous Melanoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous MelanomaActive, not recruiting

Cutaneous MelanomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Cutaneous Melanoma

#DrugCompanyPhaseTrials

Thalomid

Bayer Aspirin

Afinitor

Fludara

Plaquenil

Cotellic

Calciferol

Koselugo

Alkeran

1 10

Tasigna

AAzurity Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cutaneous Melanoma1 trial

Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study

Recruiting·AAzienda Ospedaliera di Perugia·N/A·NCT07050940·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AntiPD1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AntiPD1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AntiPD1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Azienda Ospedaliera di Perugia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAzienda Ospedaliera di Perugia

AntiPD1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cutaneous Melanoma1 trial

References

Drug Info

Quick Facts

Related News